神経内分泌腫瘍 (NET) ：市場考察、疫学、市場予測
Neuroendocrine Tumors (NETs) - Market Insights, Epidemiology and Market Forecast - 2028
|発行||DelveInsight Business Research LLP||商品コード||745229|
|出版日||ページ情報||英文 266 Pages
|神経内分泌腫瘍 (NET) ：市場考察、疫学、市場予測 Neuroendocrine Tumors (NETs) - Market Insights, Epidemiology and Market Forecast - 2028|
|出版日: 2019年09月01日||ページ情報: 英文 266 Pages||
当レポートでは、神経内分泌腫瘍 (NET) 治療薬市場について調査分析し、疾患の背景、疫学、主要7ヶ国 (米国、ドイツ、スペイン、イタリア、フランス、英国、日本) の市場動向について、体系的な情報を提供しています。
DelveInsight's 'Neuroendocrine Tumors (NETs) - Market Insights, Epidemiology and Market Forecast-2028 report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of NETs in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan.
The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Neuroendocrine Tumors (NETs) from 2017 to 2028 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.
Study Period: 2017-2028
Neuroendocrine tumors (NETs) are a complex group of tumors that develop predominantly in the digestive or respiratory tracts, but can occur in many areas of the body. These tumors arise from cells called neuroendocrine cells. Like all cancers, NETs develop when the specialized cells undergo changes causing them to divide uncontrollably and grow into an abnormal tissue mass (tumor).
The DelveInsight Neuroendocrine Tumors (NETs) market report gives the thorough understanding of the Neuroendocrine Tumors by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Neuroendocrine Tumors in the US, Europe and Japan.
The Neuroendocrine Tumors (NETs) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total prevalent population, total incident population, total diagnosed prevalent cases of Neuroendocrine Tumors, symptom based classification, diagnosed prevalent cased based on malignancy, site-specific prevalent cases, grade-specific prevalent cases and stage-specific prevalent cases) scenario of Neuroendocrine Tumors (NETs) in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017-2028.
According to DelveInsight, the total number of prevalent cases of Neuroendocrine Tumors (NETs) in 7 MM was found to be 453,191, in the year 2017.
This segment of the Neuroendocrine Tumors report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
The NETs market forecast provided in the report solely focuses on the market revenue generated by the off-label products (chemotherapy and cytotoxic agents) and targeted therapies that are being used for the treatment of NETs. The somatostatin analogs (SSAs) such octreotide and lanreotide remain the keystone of treatment for most well-differentiated, somatostatin-receptor-expressing metastatic NETs. mTOR inhibitor activity, Angiogenesis inhibitors and Radiolabeled somatostatin analog therapy form the mainstays of NET Therapy. Detailed chapters for upcoming therapies like Azedra (Progenics Pharmaceuticals), Sulfatinib (Hutchison MediPharma), Axitinib (Pfizer), RRx-001 (EpicentRx), Entrectinib (Ignyta), and Carfilzomib (Amgen) have been covered in the report.
The Neuroendocrine Tumors market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the market of Neuroendocrine Tumors in 7MM was found to be USD 3.57 Billion in 2017, and is expected to increase during the course of the study period (2017-2028). Among the 7MM, the United States accounts for the largest market size of Neuroendocrine tumors, in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
To be continued in the report….
To be continued in the report….